Experience and efficacy of SBRT for lung cancer:an analysis of 142 patients
Dong Baiqiang, Wang Jin, Xu Yujin, Hu Xiao, Du Xianghui, Shan Guoping, Shao Kainan, Bai Xue, Chen Ming
Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences; Department of Radiation Oncology,Cancer Hospital of the University of Chinese Academy of Sciences; Department of Radiation Oncology, Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou 310022, China
Abstract：Objective To evaluate the clinical efficacy and safety of stereotactic body radiation therapy (SBRT) for stage Ⅰ-Ⅱ non-small cell lung cancer. Methods Retrospective analysis of patients with early stage lung cancer who received SBRT in Zhejiang Cancer Hospital from 2012 to 2018 was conducted. The Kaplan-Meier method was used for survival analysis. The main endpoints of the study were locoregional control (LRC) and cancer specific survival (CSS). Results A total of 142 eligible cases were included,with a median BED10100Gy (100-132Gy). The median age was 75.6 years (47.2-89.0 years),among which 75 patients were aged (greater than or equal to 75 years old). The median follow-up time was 31.0 months,for patients< 75 years old and patients ≥ 75 years old. The 5-year LRC were 84.5% and 95.8% respectively,5-year CSS were 72.4% and 78.6% respectively,for patients< 75 years old and elderly patients. The systemic response was mild during treatment,no grade 4-5 adverse events occurred in all patients. The main acute side effect was radiation pneumonitis (RP) below grade 3. Grade 2 RP appeared in 14 patients (9.9%) after SBRT where grade 3 RP occurred in 2(1.4%). There was no treatment-related mortality in the SBRT group. Conclusions SBRT is a safe and effective treatment for early primary lung cancer with satisfactory rates of LRC and CSS in 5 years and mild complication,which is similar to previous reports.
Dong Baiqiang,Wang Jin,Xu Yujin et al. Experience and efficacy of SBRT for lung cancer:an analysis of 142 patients[J]. Chinese Journal of Radiation Oncology, 2020, 29(6): 416-420.
[1] Iyengar P, Timmerman RD. Stereotactic ablative radiotherapy for non-small cell lung cancer:rationale and outcomes[J]. JNCCN, 2012, 10(12):1514-1520. [2] Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer[J]. JAMA, 2010, 303(11):1070-1076. DOI:10.1001/jama.2010.261. [3] Hurkmans CW, Cuijpers JP, Lagerwaard FJ, et al. Recommendations for implementing stereotactic radiotherapy in peripheral stageⅠ a non-small cell lung cancer:report from the Quality Assurance Working Party of the randomised phase Ⅲ ROSEL study[J]. Radiat Oncol, 2009, 4:1. DOI:10.1186/1748-717x-4-1. [4] Olsen JR, Robinson CG, El Naqa I, et al. Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 81(4):e299-303. DOI:10.1016/j.ijrobp.2011.01.038. [5] Sun B, Brooks ED, Komaki RU, et al. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage Ⅰ non-small cell lung cancer:results of a phase 2 clinical trial[J]. Cancer, 2017, 123(16):3031-3039. DOI:10.1002/cncr.30693. [6] Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage Ⅰ non-small cell lung cancer:a pooled analysis of two randomised trials[J]. Lancet Oncol, 2015, 16(6):630-637. DOI:10.1016/s1470-2045(15)70168-3. [7] Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage Ⅰ nonsmall cell lung carcinoma:clinical outcomes in 245 subjects in a Japanese multi-institutional study[J]. Cancer, 2004, 101(7):1623-1631. DOI:10.1002/cncr.20539. [8] Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage Ⅰ non-small cell lung cancer:updated results of 257 patients in a Japanese multi-institutional study[J]. J Thorac Oncol, 2007, 2(7 Suppl 3):S94-100. DOI:10.1097/JTO.0b013e318074de34. [9] Shirvani SM, Jiang J, Chang JY, et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly[J]. Int J Radiat Oncol Biol Phys, 2012, 84(5):1060-1070. DOI:10.1016/j.ijrobp.2012.07.2354. [10] Zhang B, Zhu F, Ma X, et al. Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer:a systematic review and meta-analysis[J]. Radiother Oncol, 2014, 112(2):250-255. DOI:10.1016/j.radonc.2014.08.031. [11] Chi A, Liao Z, Nguyen NP, et al. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small cell lung cancer:clinical implications[J]. Radiother Oncol, 2010, 94(1):1-11. DOI:10.1016/j.radonc.2009.12.008. [12] Shibamoto Y, Hashizume C, Baba F, et al. Stereotactic body radiotherapy using a radiobiology-based regimen for stage Ⅰ non-small cell lung cancer:five-year mature results[J]. J Thorac Oncol, 2015, 10(6):960-964. DOI:10.1097/jto.0000000000000525. [13] Navarro-Martin A, Aso S, Cacicedo J, et al. Phase Ⅱ Trial of SBRT for stage Ⅰ NSCLC:Survival, Local Control, and Lung Function at 36 Months[J]. J Thorac Oncol, 2016, 11(7):1101-1011. DOI:10.1016/j.jtho.2016.03.021. [14] van den Berg LL, Klinkenberg TJ, Groen HJ, et al. Patterns of recurrence and survival after surgery or stereotactic radiotherapy for early stage NSCLC[J]. J Thorac Oncol, 2015, 10(5):826-831. DOI:10.1097/jto.0000000000000483. [15] Crabtree TD, Puri V, Robinson C, et al. Analysis of first recurrence and survival in patients with stage Ⅰ non-small cell lung cancer treated with surgical resection or stereotactic radiation therapy[J]. J Thorac Cardiovasc Surg, 2014, 147(4):1183-1192. DOI:10.1016/j.jtcvs.2013.11.057. [16] Deng XF, Jiang L, Liu QX, et al. Lymph node micro metastases are associated with disease recurrence and poor survival for early-stage non-small cell lung cancer patients:a meta-analysis[J]. J Cardiothorac Surg, 2016, 11:28. DOI:10.1186/s13019-016-0427-x. [17] Senthi S, Lagerwaard FJ, Haasbeek CJ, et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small cell lung cancer:a retrospective analysis[J]. Lancet Oncol, 2012, 13(8):802-809. DOI:10.1016/s1470-2045(12)70242-5. [18] Fernandez FG, Kozower BD, Crabtree TD, et al. Utility of mediastinoscopy in clinical stage Ⅰ lung cancers at risk for occult mediastinal nodal metastases[J]. J Thorac Cardiovasc Surg, 2015, 149(1):35-41, 42.e1. DOI:10.1016/j.jtcvs.2014.08.075. [19] Harris JP, Nwachukwu C, Qian Y, et al. Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer[J]. Lung Cancer, 2018, 124:76-85. DOI:10.1016/j.lungcan.2018.07.033. [20] Palma D, Senan S. Stereotactic radiation therapy:changing treatment paradigms for stage Ⅰnonsmall cell lung cancer[J]. CurrOpin Oncol, 2011, 23(2):133-139. DOI:10.1097/CCO.0b013e328341ee11. [21] Mattonen SA, Palma DA, Haasbeek CJ, et al. Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer[J]. Med Phys, 2014, 41(3):033502. DOI:10.1118/1.4866219. [22] Levy A, Guckenberger M, Hurkmans C, et al. SBRT dose and Survival in non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2015, 92(4):945-946. DOI:10.1016/j.ijrobp.2015.03.032. [23] Videtic GM, Chang JY, Chetty IJ, et al. ACR appropriateness Criteria (R) early-stage non-small cell lung cancer[J]. Am J Clin Oncol, 2014, 37(2):201-207. DOI:10.1097/coc.0000000000000013. [24] Verstegen NE, Lagerwaard FJ, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage Ⅰ NSCLC:comparison with a contemporaneous cohort with pathologically proven disease[J]. RadiotherOoncol, 2011, 101(2):250-254. DOI:10.1016/j.radonc.2011.09.017. [25] Timmerman RD, Hu C, Michalski JM, et al. Long-term results of stereotactic body radiation therapy in medically inoperable Stage Ⅰ non-small cell lung cancer[J]. JAMA Oncol, 2018, 4(9):1287-1288. DOI:10.1001/jamaoncol.2018.1258.
2020, Vol. 29 
